US seeks market withdrawal of Miralax generics
This article was originally published in Scrip
The US FDAis proposing to withdraw approval of generic prescription versions of the laxative polyethylene glycol because the reference product, Schering-Plough's Miralax, was switched from Rx to over-the-counter status in 2006. The ANDAs are held by Schwarz Pharma (UCB), Kali Laboratories (Par Pharmaceutical), Nexgen Pharma, Coastal Pharmaceuticals and Teva Pharmaceutical Industries. The Food, Drug and Cosmetic Act does not permit both Rx and OTC versions of the same drug product to be marketed at the same time. The agency is giving the ANDA holders an opportunity to request a hearing before withdrawing approval.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.